Gadoquatrane - Bayer
Alternative Names: AMBELVIST; BAY-1747846Latest Information Update: 17 Jun 2026
At a glance
- Originator Bayer
- Class Amides; Amines; Carboxylic acids; Contrast media; Diagnostic agents; Gadolinium-containing contrast agents; Heavy metals; Macrocyclic compounds
- Mechanism of Action Magnetic resonance imaging enhancers
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Registered CNS disorders; Unspecified
Most Recent Events
- 15 Jun 2026 Gadoquatrane contains boxed warning for intrathecal administration and nephrogenic systemic fibrosis and is contraindicated in patients with a history of severe hypersensitivity reactions
- 15 Jun 2026 Registered for CNS disorders (Diagnosis, In children, In adults, In neonates, In the elderly, In infants, In adolescents) in USA (IV)
- 15 Jun 2026 Registered for Unspecified (In infants, In adults, In neonates, In children, In the elderly, Diagnosis, In adolescents) in USA (IV)